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Epsilon toxin (Etx) from Clostridium perfringens is a pore-forming protein that 29 
crosses the Blood-Brain Barrier, binds to myelin and hence, has been 30 
suggested as a putative agent for the onset of multiple sclerosis, a 31 
demyelinating neuroinflammatory disease. Recently, Myelin and Lymphocyte 32 
protein (MAL) has been identified as a key protein in the cytotoxic effect of Etx, 33 
however the association of Etx with the immune system remains a central 34 
question. Here, we show that Etx selectively recognizes and kills only human 35 
cell lines expressing MAL through a direct Etx-MAL interaction. Experiments on 36 
lymphocytic cell lines reveal that MAL expressing T cells, but not B cells, are 37 
sensitive to Etx, and revealed the toxin as a molecular tool to distinguishing 38 
subpopulations of lymphocytes. The overall results open the door to investigate 39 
the role of Etx and Clostridium perfringens on inflammatory and autoimmune 40 
















Epsilon toxin (Etx) from Clostridium perfringens toxinotypes B and D is the most 54 
powerful toxin after botulinum and tetanus toxins, mainly affecting ruminants 55 
causing important economic losses (1). The toxin is produced by the bacteria 56 
present in the guts of young animals leading to fatal enterotoxemia in sheep, 57 
goat and cattle (2, 3). It is synthesized as a non-toxic protein precursor, epsilon-58 
prototoxin (pEtx), which is activated upon proteolytic cleavage at the N and C-59 
terminal regions (4). 60 
In addition to its effect on livestock, Etx has a lethal activity when injected into 61 
experimental animal models, basically, rodents. Etx bypasses the transit 62 
through the digestive system and causes a generalized edema, neurological 63 
disorders and, finally, the death of the animal, being the lethal dose in mice (one 64 
of the most used animal model for Etx studies) around 100 ng/Kg (5). At the 65 
cellular level, Etx is a member of the aerolysin-like ß-pore forming toxin family 66 
(6). Etx form pores in lipid planar bilayers and therefore in the plasma 67 
membrane of sensitive cells after its specific binding and further oligomerization, 68 
producing cell permeability, ionic diffusion, ATP depletion and cell death (7, 8). 69 
The toxin also has the capacity to cross the Blood-Brain Barrier (BBB) and bind 70 
to cerebral myelin (9, 10). Moreover, “in vitro” experiments using primary cell 71 
cultures and brain explants, demonstrate the demyelination capacity of Etx and 72 
eventually a cytotoxic effect on oligodendrocytes (10, 11), the myelin forming 73 
cells in the central nervous system. These and other evidences have been used 74 
as arguments to suggest Etx as a putative agent for the onset of multiple 75 




In addition to the effect of Etx on oligodendrocytes, few cell lines have been 77 
defined to be sensitive to Etx and identified as potential targets of its cytotoxic 78 
activity. Among them, the most sensitive cell line is MDCK (Madin-Darby 79 
Canine Kidney), a renal epithelial distal tubule cell line from canine origin, which 80 
has been widely used to study the cellular and molecular mechanism of Etx 81 
cytotoxicity (8). This characteristic of the renal cell line correlates with the 82 
observed “in vivo” cytotoxic effect of Etx on renal distal tubular cells in Etx 83 
injected mice (13, 14). Other cell lines sensitive to Etx but with a variable 84 
cytotoxic effect depending on the cell model include the mouse kidney cell line 85 
mpkCCDc14
 (15), the Caucasian renal leiomyoblastoma (G-402) human cell line 86 
(16), primary cultures of human renal tubular epithelial cells (HRTEC) (17) and 87 
the human renal adenocarcinoma cell line ACHN (18) among others. 88 
It is assumed that the specific action of Etx on sensitive cells relies on the 89 
presence of an Etx receptor to selectively bind the cell surface before the 90 
formation of the oligomer. In spite of the proposed role of membrane lipids in 91 
the recognition or affinity of Etx to the cell targets (19-21), a set of proteins has 92 
been explored as potential receptors for Etx, which can account for the full and 93 
high sensitive effect of the toxin. Among them, the most promising candidates 94 
are the hepatitis A virus cellular receptor 1 (HAVCR1) (18), and the Myelin and 95 
Lymphocyte protein (MAL) (22). While a complete functional evidence for 96 
HAVCR1 as an Etx receptor mediating its cytotoxic activity is elusive (23), the 97 
transfection of MAL protein confers sensitivity to otherwise unresponsive cell 98 
lines (22). In addition, KO mice for MAL protein survive after intraperitoneal 99 




protein (MAL) has been defined as a key protein in the cytotoxic effect of Etx, 101 
either as a putative receptor or as an effector protein (23). 102 
MAL is a tetraspanning membrane protein of 17 kDa initially identified as a 103 
marker of human T cell maturation (24). This protein is also present in 104 
myelinating oligodendrocytes, myelin and in some epithelial cells (i.e., urothelial 105 
and renal tubules) where it has been involved in membrane traffic, especially for 106 
apical transport of membrane and secretory proteins and lipid raft cycling (25, 107 
26). The presence of MAL protein in myelin structures and myelinating 108 
oligodendrocytes would explain the specific binding of Etx to myelin (9) and the 109 
demyelinating effect of the toxin (10, 11). The presence of MAL protein in 110 
lymphocytes has been mainly linked to the maturation of T-cells (24), 111 
intracellular membrane traffic (27) or the exosome secretion (28). However, the 112 
possible effect of Etx on MAL expressing lymphocyte derived cells is not known. 113 
In the present paper, we further explore by several methods whether the 114 
cytotoxic ability of Etx from Clostridium perfringens is exclusively dependent on 115 
the expression of MAL protein. Moreover, evidence of a direct interaction of 116 
MAL protein with Etx is provided by means of immunoprecipitation assays. 117 
These results led us explore the sensitivity of cell lines from lymphocytic origin 118 
to Etx, which naturally express or not MAL protein, and demonstrate that this 119 
protein is sufficient for Etx cytotoxic activity. The study of cell types that 120 
naturally express MAL protein would give a new light on the Etx action 121 









MAL is required for Etx Binding 128 
To characterize the MAL-dependent cytotoxic effect of Etx, three cell lines 129 
which do not express MAL protein (tsA201, RT4-D6P2T and HeLa) were stably 130 
transfected, for the expression of human MAL protein (hMAL) fused to Green 131 
Fluorescent Protein (GFP), hMAL-GFP. Mock transfected cells (GFP) were 132 
used as controls.  133 
Transfected cells were positively selected with 0.5 mg/mL Geneticin/ G418 134 
before cell sorting was performed and the most positive cells expressing hMAL-135 
GFP were collected, maintained and used for further experiments. The 136 
effectiveness of hMAL-GFP expression was monitored by western blot analysis 137 
using anti-GFP and anti-MAL-E1 antibodies (Figures 1A and 1B, respectively). 138 
Confocal microscopy images revealed the expression of hMAL-GFP protein 139 
mostly localized in the cell plasma membrane, while GFP was localized in the 140 
cytosol and nuclei in mock transfected cells (Figure 1C).  141 
Etx labelled with DyLight 633 (Etx-633) was used to verify the binding of Etx to 142 
positive hMAL-GFP expressing cells. As expected, the toxin was bound to the 143 
cell lines expressing hMAL-GFP but not to the GFP control cell lines. Most of 144 
the Etx labeling was localized in the periphery of the cells, matching the 145 
distribution of hMAL-GFP (Figure 1C).  146 
 147 
Etx produces cytotoxicity in hMAL expressing cells  148 
The cytotoxic effect of Etx is based on the selective binding to the target cell, 149 
the oligomerization of the protein and the subsequent pore formation that 150 

































permeabilizes the cell plasma membrane allowing the diffusion of ions and 151 
other elements up to 2.3 kDa (29, 30). 152 
Taking advantage of the pore forming capacity of Etx, the release of ATP from 153 
cytosol or internal cell stores was measured using the luciferine-luciferase 154 
method on hMAL-GFP expressing cells, on MDCK cells used as positive 155 
controls and on GFP transfected cells used as negative controls. 156 
ATP release from MDCK cells was Etx dose and time dependent (Fig.2A). All 157 
content of ATP was released between 30 min (100 nM Etx) and 40 min (12.5 158 
nM) depending on the Etx dose. 159 
The concentrations of Etx used (from 12.5 to 100 nM) were rather high, 160 
considering the sensitivity of MDCK cell line to Etx, but this approach was very 161 
convenient because it allowed the measurement in real time of Etx-dependent 162 
ATP release in a limited time. At the end of the experiment, all ATP was virtually 163 
released by Etx and no residual ATP could be measured after cell 164 
permeabilization with Triton X-100. However, Triton X-100 released all ATP 165 
content in the case of GFP expressing cells or when pEtx was used instead of 166 
fully active Etx. These results suggest that at all concentrations used, the 167 
MDCK cells were already dead at the end of the experiment in spite of the Etx 168 
concentration used (Figure 2A). 169 
As expected, hMAL-GFP transfected cells released ATP in the presence of Etx 170 
(Figure 2B) however no ATP was released from GFP transfected cells or from 171 
those cells incubated in the presence of pEtx, even at the highest concentration 172 
used. These results support the pore formation by Etx (anionic or non-specific) 173 
in hMAL expressing cells, although the rupture of the plasma membrane by 174 
other mechanism (i.e. necrosis) cannot be discarded. 175 

































The MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-176 
sulfophenyl)-2H-tetrazolium) colorimetric assay was used in cytotoxicity assays 177 
to determine cell viability (see material and methods). The MTS assays 178 
revealed that Etx and Etx-633 showed a similar degree of cytotoxicity on hMAL-179 
GFP expressing cells, with no effect on GFP control cells. The non-active forms 180 
of the toxin, pEtx or pEtx-633 showed no toxic effects (not shown). The 181 
cytotoxic effect of Etx on hMAL-GFP transfected cell lines was similar to that 182 
observed in MDCK cells (Figure 3), although this effect was not complete in all 183 
transfected cell lines (no 100% of cell death), suggesting different levels of 184 
hMAL-GFP expression compared with the well stablished and sensitive MDCK 185 
cell line. The cytotoxicity of Etx on hMAL-GFP transfected cell lines was dose 186 
dependent with a maximum effect around 25 nM. The CT50 was calculated with 187 
a 95% confidence interval indicated as 95% CI (lower-upper). In the case of 188 
tsA201-hMALGFP CT50 was 1.26 nM (0.69-2.27), in RT4-D6P2T-hMALGFP 189 
CT50 was 2.88 nM (2.36-3.50) and finally in HeLa-hMALGFP CT50 was 3.36 nM 190 
(2.63-4.29). All of them were values not far from the CT50 calculated for MDCK 191 
cells, 0.64 nM (0.52-0.78).  192 
 193 
Direct interaction hMAL-Etx 194 
Considering that transfection of hMAL-GFP in a non-sensitive cell line is able to 195 
transform this cells into Etx sensitive (as seen in MTS assays and ATP release 196 
experiments), it was essential to search for a possible Etx-MAL interaction. 197 
In order to check a possible Etx-MAL interaction, coimmunoprecipitation (Co-IP) 198 
assays were performed with the expressing hMAL HeLa stable cell line (HeLa 199 
hMAL-GFP). Four confluent culture dishes of 10 cm diameter were grown; two 200 

































of them were exposed for 30 min to 100 mM Etx, one was exposed for 30 min 201 
to 100 mM pEtx and the last one was kept as a negative control. From all 202 
dishes, total cell extracts were obtained, inputs were kept and the rest of cell 203 
lysates were incubated with anti-GFP antibody to immunoprecipitate (IP) hMAL-204 
GFP, except in one of the extracts treated with Etx that was incubated with anti-205 
Tubulin as a negative IP control. Western blot analysis performed after 206 
immunoprecipitation using anti-pEtx antibody, revealed that Etx 207 
coimmunoprecipitate with hMAL-GFP (Figure 4). It is remarkable that Etx is 208 
detected in inputs and in coimmunoprecipitates as a large membrane complex. 209 
It is well known that Etx oligomerizes and forms a large membrane complex, as 210 
previously described in MDCK cell line (20). Etx was not detected when using 211 
the negative control antibody (anti-Tubulin). The same membrane was 212 
subsequently incubated with anti-GFP in order to check the correct 213 
immunoprecipitation of hMAL-GFP. Thus, the coimmunoprecipitation 214 
experiments indicated that Etx and MAL are able to interact. 215 
The above and previous results from other labs (22), suggest that MAL protein 216 
is required for the cytotoxic activity of Etx. If this is the case, those cells 217 
expressing MAL could be potential targets of Etx. This suggestion is especially 218 
relevant for those cells of the immune system that may be involved directly or 219 
indirectly with neuroinflammatory and autoimmune diseases. To further study 220 
this possibility, we took advantage of cell lines of lymphocytic origin that express 221 
MAL, and compared the results with cell lines of lymphocytic origin that do not 222 
express MAL. 223 
 224 
MAL protein in Lymphocytes 225 

































MAL protein was firstly identified in subsets of human lymphocyte populations, 226 
basically T derived cell lines, as the Jurkat and MOLT-4 human lymphocyte cell 227 
lines (24). Taking advantage of the naturally expression of MAL protein in these 228 
cell lines, the possible effect of Etx was studied and compared with lymphocytic 229 
cell lines that do not express MAL protein (TK6 and JeKo-1, mantle derived cell 230 
lines). The expression of MAL mRNA in MOLT-4 and Jurkat, but not in TK6 and 231 
JeKo-1 cell lines, was corroborated by RT-PCR (Figure 5A). Notice that the 18S 232 
rRNA, used as an internal control, indicate a constant expression level across 233 
all samples. 234 
The effect of Etx on lymphocytic cell lines expressing MAL protein was 235 
confirmed by the MTS cytotoxic assay (Figure 5B), the ATP release assay 236 
(Figure 5C) and flow cytometry (Figures 6A and 6B). All experimental 237 
approaches showed specific effect of Etx on Jurkat and MOLT-4 cell line, but 238 
not in TK6 and JeKo-1 cell lines, with a higher cytotoxic effect and ATP release 239 
on the MOLT-4 cell line. Compared to the effect of Etx on MDCK cell line with a 240 
CT50 of  0.64 nM (0.52-0.78) the lymphocytic Etx-sensitive cell lines were slightly 241 
less sensitive. In MOLT-4 cells, the CT50 was 11.09 nM (7.26-16.67) and in 242 
Jurkat cells the CT50 was 26.67 nM (19.04-37.4).  243 
Taking into account the sensitivity of lymphocytic MAL expressing cell lines to 244 
Etx, the possible formation of Etx oligomers, as a previous step for the pore 245 
formation, was analyzed. A western blot analysis was performed on MOLT-4 246 
and JeKo-1 cells after 30 min of 100 nM pEtx and Etx incubation (Figure 6C). 247 
Western blot analysis revealed the Etx oligomeric complex formation on MOLT-248 
4 cells but not on JeKo-1 cells nor on cells incubated with pEtx, indicating 249 

































therefore that the effect of Etx on MAL-expressing lymphocytic cell lines 250 
depends on the formation of Etx complex in the cell plasma membrane. 251 
To fully demonstrate that the expression of MAL was a condition for Etx 252 
cytotoxic effect, the MOLT-4 cell line was used to deplete the expression of the 253 
protein by the CRISPR-Cas9 method. Several clones were obtained and 254 
analyzed for the effect of Etx, either in MAL depleted clones (MOLT-4-∆MAL) or 255 
mock transfected (MOLT-4 CTL). The absence of MAL protein in the MOLT-4-256 
∆MAL clone was checked by western blot assay (Figure 7A) and the 257 
subsequent absence of Etx binding, by confocal microscopy and flow cytometry 258 
assay (Figures 7B and 7C). These experiments clearly demonstrated that the 259 
absence of MAL, directly affect Etx binding to the plasma cell membrane. 260 
Cytotoxic assay and Etx-dependent ATP release experiments on MOLT-4-261 
∆MAL and MOLT-4-CTL clones, also showed the absence of Etx cytotoxic 262 
effect when MAL protein was not expressed (Figure 8A). Moreover, the 263 
absence of membrane complex formation after incubation with Etx, was also 264 
evident in MOLT-4-∆MAL cells analyzed by western blot and compared to 265 




In this report, we show the direct interaction of epsilon toxin (Etx) from 270 
Clostridium perfringens with cells of the immune system. In humans, Etx has 271 
been involved with the onset of the neuroinflammatory and demyelinating 272 
disease, multiple sclerosis (MS) (12). As far as we know, no relationship of Etx 273 

































with the immune system and the possible involvement of this direct interaction 274 
with neuroinflammatory disease have been described before. 275 
Etx crosses the BBB and produces neurological alterations in sheep, goat, 276 
cattle, mice and rats (31-33). Moreover, Etx induces glutamate release (5, 34) 277 
either by membrane pore formation (8) or through a membrane transporter (10) 278 
or both systems, raising intracellular receptor-mediated calcium concentration 279 
and producing a cytotoxic effect (5, 8, 10, 35). In fact, lethal activity of Etx has 280 
been directly related to the neurological effect (31, 36). 281 
It is assumed that the Etx-dependent ATP release is mediated by the pore 282 
formation of Etx, after toxin oligomerization, that allows the efflux of molecules 283 
up to ~ 2300 Da from the cytosolic compartment (30). Similarly, Etx-dependent 284 
glutamate efflux from cells in the CNS has been observed, although the rise in 285 
extracellular glutamate has been also ascribed to glutamate membrane 286 
transporter without a concomitant cytotoxic effect (10). Accordingly, ATP could 287 
be, at least, partially extruded by another mechanism than through a pore 288 
formation, including membrane transporters or even by necrotic cell death 289 
shown in several pore forming toxins (37). In any case, extracellular ATP may 290 
trigger the excitotoxicity of oligodendrocytes by the activation of P2X7 291 
receptors, together with glutamate-mediated excitotoxicity (10, 38). 292 
 293 
The present report supports a direct role of MAL protein in Etx activity (22). The 294 
expression of hMAL protein in tsA201, RT4 and HeLa cell lines, that naturally 295 
do not express MAL protein, is sufficient to sensitize them to Etx and, 296 
accordingly, cells naturally expressing MAL protein are sensitive to Etx. The 297 
effect of Etx on MAL protein expressing cells was confirmed using up to three 298 

































different methods: the MTS based cell cytotoxic assay and the ATP release on 299 
transfected cell lines, together with the flow cytometry assay when lymphocytic 300 
derived cell lines were used in the study. All three methods demonstrated the 301 
cytotoxic effect of Etx in the nanomolar range only in MAL expressing cells, 302 
supporting this membrane protein as the cellular Etx receptor. Interestingly, 303 
MAL protein has been related to a defined membrane lipid composition, 304 
basically, in glycosphingolipids enriched domains, mainly galactosilceramide 305 
and sulfatide (39). Removal of the sulfate group significantly impairs Etx 306 
cytotoxic activity in MDCK cells, suggesting a close relationship between MAL 307 
protein, sulfatide and Etx (19). Moreover, MAL protein has been involved in 308 
myelin biogenesis, probably in the vesicular transport of sulfatide to the 309 
membrane forming myelin (39, 40). 310 
Genetically deficient MAL mice are resistant to Etx, suggesting that MAL is not 311 
only involved in the cytotoxic effect of Etx on defined target cells but also in its 312 
lethal effect on naturally infected and experimental animal models.  313 
As far as we know, this is the first time showing a direct effect of Etx on 314 
lymphocytic cell lineage, and in particular on T cell derived lymphocytes. 315 
Moreover, the cytotoxic effect of Etx coincides with the expression of MAL 316 
protein in the sensitive cell lines (24) and this report, being specific and 317 
dependent of MAL protein expression: MAL protein deletion in MOLT-4 cell line 318 
completely abolishes the cytotoxic effect of Etx.  319 
Which could be the consequence of Etx acting on immune T cells? Although it 320 
is still speculative, it could represent the connection between Etx and its 321 
proposed role as an agent in the onset of MS. Different possibilities can be 322 
considered: a) it may represent a situation where a direct but chronic exposure 323 

































to low Etx concentrations and the property of Etx to both bind myelin and 324 
lymphocytes may induce alteration in myelin structure, in its formation or 325 
maintenance; b) Etx could have a direct effect on oligodendrocytes, producing 326 
its malfunctioning, and even degeneration, with a consequent demyelination 327 
(10, 11) or a neuroinflammatory effect that would cause also alterations in 328 
myelin structures and subsequent demyelination; c) Etx may directly act on a 329 
defined T cell population, either producing a cytotoxic effect or activating an 330 
immune response. 331 
In the first possibility, the effect of Etx on lymphocytes would be time and 332 
concentration dependent. It could be assumed that circulating blood cells, in 333 
particular a subpopulation of T cells wearing MAL protein, would be the first cell 334 
type in contact with Etx, together with endothelial cells, once in the blood stream 335 
after toxin enters the organism even at very low amounts. Although the effect on 336 
immune cells could not be evident at such low dose and no symptoms would be 337 
visible in a short time (which could be evident when a high number of T-cell 338 
would be affected), T-cells expressing MAL could be in contact with Etx for a 339 
long time, acting as Etx carriers and eventually entering the CNS were they can 340 
interact with cells that, in turn, express MAL protein (oligodendrocytes). In the 341 
second possibility,  as stated before, Etx binds to and eventually affects 342 
endothelial cells, crosses the BBB and binds to myelin (9, 41) where it may act 343 
directly on oligodendrocytes producing demyelination (10, 11). In the third 344 
possibility, Etx would act through MAL expressing T cell direct interaction. In 345 
that case, Etx could activate a defined pool of T cells (those expressing MAL) 346 
and potentiate any of the above proposed mechanism in the onset of CNS 347 

































demyelinization, or produce a cytotoxic effect on a regulatory T cell population, 348 
increasing the probability of autoimmune reaction.  349 
We understand that these suggestions are highly speculative, but they open a 350 
new view on the onset of neuroinflammatory diseases, where particular gut 351 
microbiota component directly or indirectly interact with the immune and 352 
nervous systems, affecting particular cell functions. While Etx may be the agent 353 
responsible for a demyelinating process, other components of the microbiota 354 
may influence or precipitate its onset (42). The animal model for MS, the 355 
experimental autoimmune encephalomyelitis (EAE) is characterized by the 356 
contribution of CD4 T lymphocytes, specially Th1 and Th17 producing 357 
interferon-gamma and interleukin 17 respectively (43, 44). It is widely accepted 358 
that MS, an autoimmune disease, is triggered by autoreactive T cells, that 359 
would be antigen activated, cross the BBB and initiate an inflammatory 360 
response (45). 361 
All together, these results show a direct interaction of Etx from Clostridium 362 
perfringens with T cells expressing MAL suggesting a possible role in 363 
neuroinflamatory events and point out Etx (and pEtx) as a new marker for 364 
lymphocyte T cells lineage. 365 
 366 
MATERIALS AND METHODS 367 
 368 
Cell lines 369 
MDCK (CCL-34, ATCC): Madin-Darby canine kidney (MDCK) was used as a 370 
positive control, as is the most common sensitive in vitro model for Etx.  371 

































Three cell lines from different origin: tsA201(96121229, ECACC) from human 372 
kidney, RT4-D6P2T (CRL-2768, ATCC) from a rat schwannoma and HeLa 373 
(CCL-2, ATCC) a human epithelial cervix cell line from an adenocarcinoma, 374 
were selected because they do not express MAL protein and are insensitive to 375 
Etx. 376 
Cell lines from different lymphocyte origin were chosen because of their 377 
capacity to express or not MAL protein. TK6 (CRL-8015, ATCC) a human B 378 
lymphoblast cell line and JeKo-1 (CRL-3006, ATCC) a mantle cell lymphoma 379 
cell line, do not express MAL protein. On the other hand, Jurkat (88042803, 380 
ECACC) a human leukaemic T cell lymphoblast cell line and MOLT-4 381 
(85011413, ECACC) a human acute T lymphoblastic leukemia cell line, both 382 
express MAL protein.  383 
 384 
MDCK (CCL-34, ATCC), tsA201(96121229, ECACC), RT4-D6P2T (CRL-2768, 385 
ATCC) and HeLa (CCL-2, ATCC) cell lines were maintained in DMEM-F12 386 
medium containing 15 mM Hepes and 2.5 mM L-Glutamine (Gibco), 387 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Biological 388 
Industries) and 1% Penicillin/Streptomycin (P/S) (Sigma-Aldrich).  389 
TK6 (CRL-8015, ATCC), Jurkat (88042803, ECACC), MOLT-4 (85011413, 390 
ECACC) and JeKo-1 (CRL-3006, ATCC) cells were maintained in RPMI 391 
medium (Gibco), supplemented with 10% (FBS) (Biological industries).  392 
Cells were all grown at 37ºC in a humidified atmosphere of 5% CO2. 393 
Cell lines including tsA201, RT4-D6P2T, HeLa, were used to obtain stably 394 
transfected cells for the expression of pEGFPN1-hMAL, or pEGFPN1 as a 395 
negative control. Cells were transfected using Lipofectamine 2000 (Invitrogen). 396 

































After transfection, cells were selected with 0.5 mg/mL Geneticin/G-418 (Gibco). 397 
Homogenous GFP expressing cells were obtained using the cell sorter MoFlo 398 
Astrios (Beckman Coulter) at CCiTUB, Biology Unit of the Bellvitge Campus, 399 
University of Barcelona.  400 
 401 
Expression of cDNA constructs of pEtx and GFP-pEtx 402 
Expression vectors to produce a recombinant protein with a 6 Histidine tag at 403 
the pEtx or GFP-pEtx C terminal were generated based on previously described 404 
plasmids (41). Plasmids were transformed into a RossetaTM(DE3)pLysS 405 
Escherichia coli strain for optimum protein expression. The expression of pEtx 406 
or GFP-pEtx recombinant protein was induced overnight at room temperature in 407 
250-ml LB medium cultures containing 1mM isopropyl-ß-D-408 
thiogalactopyranoside. Cells were pelleted and resuspended in ice cold 409 
phosphate buffer (PB) 0.01M NaH2PO4, 0.01M Na2HPO4 pH 7.4, containing 250 410 
mM NaCl, sonicated and centrifuged at 15,000 g for 20 min at 4°C. The 411 
resulting supernatant was incubated with 0.5 ml of previously equilibrated 412 
TALON® Metal Affinity Resin previously washed with PB and eluted with PB 413 
containing 250 mM imidazole. The eluate was dialyzed with Phosphate Buffered 414 
Saline (PBS)  0.01 M phosphate buffer, 0.150 mM NaCl and 2,7 mM KCl at final 415 
pH 7.4, to eliminate imidazole and final protein content was quantified, analyzed 416 
by SDS-PAGE and stored at -20°C, until used. Full active toxin was obtained by 417 
trypsin proteolysis of pEtx or GFP-pEtx, using trypsin beads (Sigma-Aldrich), 418 
according to the manufacturer’s instructions. The toxicity of pEtx and GFP-pEtx 419 
and their respective activated toxins were tested in MDCK cells as described 420 

































elsewhere (14). The process of purification was performed following the 421 
guidelines of biosecurity of the University of Barcelona. 422 
 423 
Cloning pEGFPN1-hMAL 424 
hMAL coding sequence (CDS) was obtained by Polymerase chain reaction 425 
(PCR) using 2 µL of a human cDNA brain library as template, 25 µL KOD Hot 426 
Start DNA Polymerase (Merck Millipore), 1,5 µL oligonucleotides at 10 µM, in a 427 
final 50 µL reaction volume. The oligonucleotides used were: 428 
Forward, 5’-GCGAGATCTATGGCCCCCGCAGCGGCGACGGGGGG-3’ 429 
(containing BglII target) and  430 
Reverse,5’-431 
GCGGTCGACTGTGAAGACTTCCATCTGATTAAAGAGAACACCGC-3’ 432 
(containing SalI target).  433 
The reaction was carried out using the following parameters: 95ºC for 2 min, 40 434 
cycles of 95ºC 20 s, 60ºC 10 s and 70ºC for 10 s. hMAL PCR was purified using 435 
QIAquick® Gel Extraction Kit (Qiagen). Purified PCR was digested with BglII-436 
SalI restriction enzymes (Thermo Scientific) and the same enzymes were used 437 
to clone hMAL into pEGFPN1. Finally, pEGFPN1-hMAL construct was 438 
sequenced to confirm DNA sequence and to check DNA insert orientation. 439 
 440 
MAL protein detection by western blot analysis 441 
MAL protein expression in hMAL-GFP stably transfected cell lines was detected 442 
by western blot analysis. Confluent 10 cm diameter culture plates were washed 443 
twice with Phosphate Buffered Saline (PBS). Cells were scraped with a cell 444 
scrapper (TPP) maintaining the cell plate on ice and adding 500 µL of RIPA 445 

































buffer (25 mM Tris-HCl pH 7.4 , 150 mM NaCl, 1% NP40, 10% SDS, 1% 446 
sodium deoxycholate) supplemented with 1:100 Protease inhibitor cocktail 447 
(#P8340, Sigma-Aldrich). Scrapped cells were set into a 1.5 mL tube and 448 
incubated on ice for 30 min. Cells were disrupted by repeated aspiration 449 
through a 29-gauge (29G) needle and centrifuged at 20,000 x g 15 min at 4ºC. 450 
Pellet was discarded and supernatants, corresponding to total cell lysates, were 451 
quantified using the Pierce™ BCA Protein Assay Kit (Thermo Scientific). From 452 
total cell lysates, 30 µg were electrophoresed in a 10 % polyacrylamide SDS-453 
PAGE gel, transferred to a nitrocellulose membrane and analyzed by western 454 
blot. Rabbit polyclonal anti-GFP-tag (1:500 dilution, # A-11122, Invitrogen) and 455 
mouse monoclonal anti-MAL-(E1) (1:500 dilution, # sc-390687, Santa Cruz) 456 
followed by secondary polyclonal swine anti-rabbit Immunoglobulins/HRP or 457 
polyclonal rabbit anti-mouse Immunoglobulins/HRP respectively (1:2000 458 
dilution, #P0217 or #P0161, Dako) were used. 459 
The analysis of MAL endogenous protein expression in MOLT-4 cells was 460 
performed using a detergent-resistant membranes (DRMs) enrichment protocol. 461 
Cells were lysed at 4ºC in 200 µL of lysis buffer containing 1% Triton X-100, 0.5 462 
mM EDTA, 1:100 Protease inhibitor cocktail (#P8340, Sigma-Aldrich). Lysates 463 
were passed through a 29G needle several times. The insoluble material (Pellet 464 
I: nuclei, cytoskeleton, DRMs and unbroken cells) was collected by 465 
centrifugation at 20,000 x g for 15 min at 4ºC and the supernatant was 466 
discarded. The sediment was resuspended in the lysis buffer supplemented 467 
with 60 mM octylglucoside and incubated at 37ºC for 30 min to extract DRMs. 468 
The resuspended pellet was centrifuged at 20,000 x g for 15 min at 4ºC. Pellet 469 
was discarded and supernatant with the extracted rafts containing MAL was 470 

































collected. From total cell lysates, 30 µg were electrophoresed in a 12% 471 
polyacrylamide SDS-PAGE gel, transferred to a nitrocellulose membrane and 472 
analyzed by western blot. The primary antibodies used were mouse monoclonal 473 
anti-MAL-(E1) (1:500 dilution, #sc-390687, Santa Cruz) and mouse monoclonal 474 
anti-Flotillin-1, as a loading control (1:1000 dilution, #610821, BD Bioscience). 475 
In both cases, the primary antibody was followed by secondary antibody 476 
incubation with polyclonal rabbit anti-mouse Immunoglobulins/HRP (1:2000 477 
dilution, #P0161, Dako).  478 
Signal from western blot membranes was developed with 479 
Luminata™Crescendo western HRP substrate (Millipore) and detected using an 480 
Amersham Imager 600 (GE Healthcare Life Sciences). 481 
 482 
Etx Immunolocalization  483 
tsA201, RT4-D6P2T and HeLa transfected cells were grown to confluence on 484 
coverslips. Cells were washed three times with PBS and fixed with 4% 485 
paraformaldehyde (PFA) for 15 min at Room Temperature (RT). After 3 486 
washings with PBS, cells were blocked by adding PBS containing 0.2% gelatin, 487 
20% normal goat serum (NGS) and 0.05% Triton X-100 for 1 h at RT. Next, 488 
cells were incubated with 200 nM of Etx labelled with DyLightTM 633 (Etx-633) in 489 
PBS containing 0.2% gelatin, 1% NGS, 0.05% Triton X-100 for 1h at RT. After 490 
three washes with PBS, coverslips were mounted with Fluoromount aqueous 491 
mounting medium (#F4680, Sigma-Aldrich). Etx was labeled with DyLight™ 633 492 
NHS Ester (#46414, Thermo Scientific) following manufacturer’s instructions. 493 
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Etx immunolocalization on MOLT-4 CTL and MOLT-4 ∆MAL cells was 495 
performed starting from 2 x 106 cells. Cells were pelleted at 1,000 x g for 3 min 496 
at 4ºC, washed twice with 1 mL PBS and fixed with 500 µL of 4% PFA at RT for 497 
15 min. After fixation, cells were pelleted at 1.000 x g and washed three times 498 
with 1 mL PBS containing 1% of Bovine Serum Albumin (PBS-1% BSA). A 499 
blocking step with Buffer A (PBS 1X, 0.2% gelatin, 20% Normal Goat Serum 500 
(NGS), 3% BSA, 0.05% Triton X-100) was done at RT for 1h followed by an 501 
incubation at RT with 500 µL of 100 nM GPF-pEtx in Buffer A for 45 min. After 502 
toxin incubation cells were stained with 500 µL of DRAQ5 (1:2000 dilution, 503 
#108410, Abcam) in Buffer A for 15 min at RT. Six washing steps were done by 504 
centrifugation at 1,000 x g with 1 mL of PBS-1% BSA and 0.05% Triton X-100. 505 
Finally, pellet was resuspended with 20 µL of Fluoromount aqueous mounting 506 
medium (#F4680, Sigma-Aldrich) and placed on a coverslip.  507 
Samples were analyzed by confocal microscopy in a Leica TCS-SL spectral 508 
confocal microscope at CCiTUB, Biology Unit of the Bellvitge Campus, 509 
University of Barcelona. 510 
 511 
hMAL-CRISPR-Cas9 512 
hMAL sgRNAs were designed using the sgRNA Scorer 2.0 CRISPR Design 513 
Tool (46). Several sgRNA sequences were obtained. From the list, two hMAL-514 
sgRNA were selected; one matching in the 5’UTR and the other in the CDS, in 515 
a common sequence of hMAL mRNA variants.  516 
hMAL-5’UTR-sgRNA: CCCTGCTCTTAACCCGCGCGCGG, and hMAL-CDS-517 
sgRNA: GCCCCCGCAGCGGCGACGGGGGG. (Underlined nucleotides 518 
correspond to PAM sequences and were eluded to design oligonucleotides).  519 


































Oligonucleotides, including the selected sequences and overhangs for the 521 
ligation step into the pair of BbsI, were phosphorylated, annealed and cloned 522 
into a pSPCas9(BB)-2A-GFP vector (Adgene plasmid ID:48138) as described in 523 
Ran et. al. (47). Both hMALsgRNA constructs: hMAL-5’UTRsgRNA-524 
pSPCAS9(BB)-2A-GFP and hMAL-CDSsgRNA-pSPCAS9(BB)-2A-GFP, were 525 
cotransfected into MOLT-4 cells by electroporation to obtain MOLT-4 ∆MAL 526 
cells. In parallel an empty pSPCAS9(BB)-2A-GFP vector was also transfected 527 
into MOLT-4 cells to obtain a MOLT-4 CRIPSR control cell line, MOLT-4 CTL. 528 
Cells were transfected by electroporation using Gene Pulser® with 4 mm gap 529 
cuvettes (BioRad), at 300 V, 10 ms, 1 pulse in ECM 830 Electro Square 530 
Porator™ (BTX) electroporator. 531 
After 24 h of transfection, a pool of positive GFP cells was selected using the 532 
cell sorter MoFlo Astrios (Beckman Coulter) at CCiTUB, Biology Unit of the 533 
Bellvitge Campus, University of Barcelona. Afterwards, a clonal selection from 534 
the positive GFP pools was done using the same cell sorter. Clones were 535 
functionally checked performing cytotoxicity assays. 536 
 537 
Cytotoxicity assays  538 
The cytotoxic effect of Etx was measured using the MTS (3-(4, 5-539 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-540 
tetrazolium) colorimetric assay. Cells were set into 96-well cell culture plate at 541 
confluence (tsA201, RT4-D6P2T and HeLa cells) or 80.000 cells/well for 542 
lymphoid cell lines in 100 µL RPMI (Gibco) supplemented with 10% FBS 543 
(Biological Industries), media. Cells were exposed to increasing concentrations 544 

































of Etx (0, 6.25, 12.5, 25, 50 and 100 nM) for 1-2 h at 37ºC. Controls were 545 
obtained by omitting Etx in each condition (100% of cell viability) or by adding 546 
0.1% TritonX-100 (100% of cell lethality). After incubation, 20 µL CellTiter 96® 547 
AQueous One Solution Cell Proliferation Reagent Solution (#G3581, Promega) 548 
were added to each well. The amount of formazan product obtained from the 549 
reaction, was recorded spectrophotometrically at 490 nm in a Microplate reader, 550 
Biochrom® Asys UVM 340 (Biochrom), at CCiTUB, Biology Unit of the Bellvitge 551 
Campus, University of Barcelona.  552 
The absorbance obtained was directly proportional to the number of living cells 553 
in culture. Triplicates of the assay were performed in three independent 554 
experiments for each condition. Statistics were determined by nonlinear 555 
regression analysis using a two-way ANOVA followed by Tukey’s multiple 556 
comparisons test. 557 
CT50 values for cytotoxicity tests were determined from MTS assays 558 
absorbance values using a nonlinear regression model (curvefit) based on 559 
sigmoidal dose response curve, log (inhibitor) versus normalized response. 560 
CT50 was calculated with a 95% confidence interval indicated as 95% CI (lower-561 
upper). 562 
 563 
Luciferin-luciferase detection assay 564 
Etx-dependent ATP release from cells was measured using the Luciferin-565 
Luciferase method.  566 
Adherent cells (tsA201, RT4-D6P2T, HeLa) were plated into a black 96 well 567 
plate with clear flat bottom and grown into confluence in 100 µL medium, in 568 

































case of suspension cells (JeKo-1, TK6, MOLT-4 and Jurkat), 80,000 cells/well 569 
were seeded in 100 µL of medium.  570 
Luciferase extract lantern from Photinus pyralis (Sigma-Aldrich) was 571 
resuspended at 0.1 µg/µL and desalted in a 10 mL 10 DG column (Bio-Rad). D-572 
luciferin (Sigma-Aldrich) was diluted at a concentration of 0.7 µg/µL in ultrapure 573 
water and was adjusted with NaOH to a final PH 7.4. 574 
A mixture of 5 µL of D-luciferin and 5 µL of luciferase were added in each cell 575 
well. Light emitted when ATP reacted with luciferin and luciferase was recorded 576 
in a FLUOstar OPTIMA Microplate Reader (BMG) at CCiTUB, Biology Unit of 577 
the Bellvitge Campus, Universitat Barcelona. Once the basal recording signal 578 
was stable, pEtx or Etx were added to each well to obtain the desired final 579 
concentration. When the peak of bioluminescence returned to the basal level, 580 
Triton X-100 was added to evaluate the content of ATP still present into cells. 581 
Each condition was run in triplicates in three independent experiments. 582 
Statistics were determined by nonlinear regression analysis using a two-way 583 
ANOVA, followed by Sidak’s multiple comparisons test.  584 
 585 
Oligomer complex formation  586 
Etx cytotoxic activity is correlated with the formation of large membrane 587 
complexes (20). To observe the formation of Etx complexes in the plasma 588 
membrane, cells were grown, and incubated with pEtx and Etx at 100 nM for 30 589 
min h at 37ºC. Cells were pelleted by centrifugation at 800 x g, washed once 590 
with PBS and centrifuged at 800 x g. Pellets were resuspended with 500 µL of 591 
RIPA buffer supplemented with 1:100 Protease inhibitor cocktail (#P8340, 592 
Sigma-Aldrich), maintained on ice 30 min and homogenized by passage 593 

































through a 29-gauge needle. The lysed cells were centrifuged at 20,000 x g 15 594 
min. Supernatants, corresponding to total cell lysates, were quantified by 595 
Pierce™ BCA Protein Assay Kit (Thermo Scientific). 30 µg of total cell lysates 596 
and 1 ng of recombinant pEtx and Etx as controls to detect correct band size 597 
were electrophoresed in a 10% polyacrylamide SDS-PAGE gel and were 598 
transferred to nitrocellulose membranes. Membranes were analyzed by western 599 
blot using a rabbit polyclonal anti-pEtx (14) pre-adsorbed to cell extracts (1:500 600 
dilution), followed by polyclonal swine anti-rabbit immunoglobulins/HRP 601 
(1:15000 dilution, #P0217, Dako). The same membranes were developed with 602 
anti-Tubulin Clone DM 1A (1:2000 dilution, #T9026, Sigma-Aldrich) followed 603 
by rabbit anti-mouse Immunoglobulins/HRP (1:15000 dilution, #P0161, Dako) to 604 
obtain the loading control. Membranes were developed with 605 
Luminata™Crescendo western HRP substrate (Millipore) and signal was 606 
detected using an Amersham Imager 600 (GE Healthcare Life Sciences). 607 
 608 
Coimmunoprecipitation 609 
The association of Etx and MAL was studied by coimmunoprecipitation (co-IP), 610 
which allows the study of protein-protein interactions. In Co-IP the complexes 611 
containing the target protein are incubated with an antibody, then Sepharose 612 
protein A or protein G beads are added to adsorb the antibody-protein 613 
complexes which are obtained by centrifugation. Protein components in the 614 
complexes are visualized by western blot analysis using specific antibodies 615 
raised against the different components. 616 
HeLa-GFP (HeLa-pEGFPN1) and HeLa-MALGFP (HeLa-pEGFPN1-hMAL) 617 
cells were grown to confluence in 10 cm diameter cell culture dishes. From four 618 

































HeLa-pEGFPN1-hMAL cell culture dishes, one was incubated for 30 min at 619 
37ºC with pEtx at 100 nM, two with Etx at 100 nM, and the fourth was kept as a 620 
negative control. Cells were washed once with PBS,. scraped and resuspended 621 
with 500 µL of RIPA buffer supplemented with protease inhibitor cocktail 622 
(#P8340, Sigma-Aldrich). Cells were collected in a 1.5 mL tube and maintained 623 
on ice for 30 min. Suspensions were disrupted by repeated aspiration through a 624 
29-gauge needle. The lysed cells were centrifuged at 20,000 x g for 15 min, and 625 
the pellet was discarded. From the cell lysates, 20 µL (4% total volume) of each 626 
condition were separated as input samples and 10 µL of 3x protein loading 627 
buffer (187.5 mM Tris-HCl pH 6.8, 2% SDS, 0.006% bromophenol blue, and 628 
30% glycerol) containing 1% β-Mercaptoethanol were added to each input.  629 
A pre-clear lysate was obtained by adding 20 µL of Protein G Plus/Protein A 630 
Agarose Suspension beads (# IP-05, Merck) to the samples, which were 631 
incubated on a rotating device at 4ºC for 1 h. Beads were pelleted by 632 
centrifugation at 1,000 x g for 2 min at 4ºC. Supernatants were transferred to a 633 
1.5 mL tube and 2 µg of mouse monoclonal anti-GFP, clone GFP-20 (# G6539 634 
Sigma-Aldrich) were added to all tubes except in one tube, previously incubated 635 
with 100 nM Etx, that was incubated with 2 µg of mouse monoclonal anti-636 
Tubulin Clone DM 1A (#T9026, Sigma-Aldrich) as a negative control. Tubes 637 
were incubated overnight on a rotating device at 4ºC. A volume of 30 µL of 638 
Protein G Plus/Protein A Agarose suspension beads was added to each tube 639 
and incubated at 4ºC in a rotating device for 2 h. Immunoprecipitates adsorbed 640 
to beads were collected by centrifugation at 1.000 x g for 2 min at 4ºC. 641 
Supernatants were carefully aspirated and discarded. Pellets were washed 4 642 
times with 1 mL RIPA buffer, each time repeating the above centrifugation step. 643 

































After the final wash, supernatants were aspirated and the resulting pellets were 644 
resuspended in 20 µL protein loading buffer containing 1% ß-Mercaptoethanol. 645 
All samples, were heated for 5 min at 95 ºC, and centrifuged at 1,000 x g for 2 646 
min at 4 ºC to separate the agarose beads. Inputs, supernatants and 647 
recombinant proteins pEtx and Etx were loaded in a 10% polyacrylamide SDS-648 
PAGE gel, transferred to a nitrocellulose membrane and detected by western 649 
blot analysis with anti-pEtx rabbit polyclonal antibody pre-adsorbed to cell 650 
extracts (1:500 dilution) (14), followed by secondary polyclonal swine anti-rabbit 651 
Immunoglobulins/HRP (1:15000 dilution, #P0217, Dako), to reveal the 652 
coimmunoprecipitated and Etx.  653 
Afterwards, the same membrane was re-blotted to check the 654 
immunoprecipitated MAL-GFP with mouse monoclonal anti-GFP clone GFP-20 655 
(1:500 dilution, # G6539, Sigma-Aldrich) followed by secondary polyclonal 656 
rabbit anti-mouse Immunoglobulins/HRP (1:15000 dilution, #P0161, Dako).  657 
Signal from membranes was developed with Luminata™Crescendo western 658 
HRP susbtrate (Millipore) and detected using an Amersham Imager 600 (GE 659 
Healthcare Life Sciences). 660 
 661 
RT-PCR  662 
A total RNA extraction was realized in TK6, JeKo-1, MOLT-4 and Jurkat-1 cells 663 
using the RNeasy Mini Kit (Qiagen) following manufacturer’s instructions.  664 
The concentration of each sample was recorded spectrophotometrically at 260 665 
nm in a Nanodrop2000C spectrophotometer (Thermo Scientific). A 666 
retrotranscription reaction (1.5 µg RNA) was carried out by using the RevertAid 667 
First Strand cDNA Synthesis Kit (Thermo Scientific) following the protocol 668 

































provided by the supplier. PCRs were performed using PCR Master Mix 2x 669 
(Thermo Scientific) to detect the presence of hMAL cDNA or 18S rRNA.  670 
hMAL primers:  671 




18S rRNA primers:  676 
18S Forward: 5’-CGCAGAATTCCCACTCCCGACCC-3’ and 18S Reverse: 5’-677 
CCCAAGCTCCAACTACGAGC-3’. 678 
The reactions were carried out using the following parameters: 95ºC for 2 min, 679 
40 cycles of 95ºC 20 s, 62ºC 10 s and 70ºC for 10 s. Amplicons were detected 680 
in a 2 % agarose gel electrophoresis.  681 
 682 
Flow Cytometry 683 
The flow cytometry experiments to analyze the sensitivity of cells to Etx were 684 
performed starting with 6 x 106 cells/ tube. Cells were incubated with 100 nM of 685 
Etx-633 in RPMI medium supplemented with 10% FBS for 20 min. Cells were 686 
centrifuged at 1.500 x g for 5 min at 4ºC and washed with 1mL PBS-1% BSA, 687 
twice. Finally, 5µL of 7AAD (7-Aminoactinomycin) (Invitrogen) were added 688 
before flow cytometry analysis. Triplicates of the assay were performed in three 689 
independent experiments and statistics were determined by nonlinear 690 
regression analysis using a two-way ANOVA followed by Dunnett’s multiple 691 
comparisons test.  692 

































To check the binding of Etx to different cell lines cells were incubated during 20 693 
min with 100 nM of Etx-633 in RPMI medium supplemented with 10% FBS and 694 
3% BSA,  centrifuged at 1.500 x g for 5 min at 4ºC and washed with 1mL PBS 695 
1% BSA, twice. Cells were fixed with 4% PFA for 15 min at RT. After fixation, 696 
cells were pelleted at 1.500 x g and washed three times with 1 mL of PBS-1% 697 
BSA. A blocking step with Buffer A (PBS 1X, 0.2% gelatin, 20% Normal Goat 698 
Serum (NGS), 3% BSA, 0.05% Triton X-100) was done for 30 min at RT 699 
followed by an incubation with mouse monoclonal anti-MAL 6D9 antibody 700 
(1:300 dilution) (48) for 30 min at RT in 500 µL of Buffer A. After three washes, 701 
cells were centrifuged at 1500 x g and the pellet was resuspended with PBS-1% 702 
BSA. Secondary antibody incubation was performed with goat anti-mouse Alexa 703 
488 (1:2000 dilution, #A11029, Invitrogen) in Buffer A. Finally, cells were 704 
washed three times with PBS-1% BSA. Samples were analyzed in BD FACS 705 
Canto (BD Biosciences, San Diego/California, United States) at the Biology Unit 706 
of the Bellvitge Campus, University of Barcelona and data was analysed using 707 
the FlowJo software (FlowJo LLC, Ashland, Oregon, United States). 708 
 709 
Quantification and Statistical Analysis 710 
Statistical parameters, including assays, n values, comparison tests and 711 
statistical significance are reported in the detailed methods section, Figures and 712 
Figure Legends. In Figures, asterisks denote statistical significance as 713 
calculated by nonlinear regression analysis using a two-way ANOVA test and 714 
each p value is indicated in Figure Legends. 715 
All statistics were analyzed using GraphPad Prism version 7.00 for Windows, 716 
GraphPad Software, La Jolla, California, USA.  717 
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FIGURE LEGENDS 889 
 890 
Figure 1. Specific binding of Etx to the plasma membrane of hMAL-GFP 891 
expressing cells lines. 892 
(A, B) Western blot analysis of stable tsA201, RT4-D6P2T and HeLa cell lines 893 
expressing either GFP or hMAL-GFP. (A) Expression of GFP (27kDa, arrow) 894 
and hMAL-GFP (44 kDa, arrowhead) was detected with anti-GFP (B) 895 
Expression of hMAL-GFP (44 kDa, arrowhead) detected with anti-MAL-(E1). (C) 896 
Confocal microscopy images from tsA201, RT4-D6P2T and HeLa cells 897 
expressing hMAL-GFP or GFP and incubated with 100 nM of labeled Etx-633, 898 
for 1 hour, see methods. The hMAL-GFP protein (green) exquisitely colocalized 899 
with Etx-633 (red) on the plasma membrane while the Etx-633 signal was not 900 
detected in control cells, which only express GFP. Scale bar corresponds to 25 901 
µm. 902 
 903 
Figure 2.  Etx-dependent ATP release from MDCK cells and from cell lines 904 
tsA201, RT4-D6P2T and HeLa- expressing hMAL-GFP. 905 
 (A) ATP release from MDCK cells. MDCK cells were incubated with different 906 
concentrations of Etx (arrow indicates Etx addition); the release of ATP was 907 
monitored continuously as light emission (A.U. arbitrary Units of luminescence). 908 
Etx produced the release of ATP from treated cells at all concentrations used, 909 
although kinetics was accelerated at higher Etx concentrations. No ATP release 910 
was recorded when MDCK cells were incubated with pEtx at a concentration 911 
equivalent to the maximum of the Etx used or when Etx was not added to the 912 
incubation medium (0 nM). Insert: at the end of experiment, Triton X-100 was 913 

































added (0.2% final concentration, arrowhead) to release the remaining ATP. The 914 
release of the ATP content was clearly observed in control cells (0 mM) and 915 
when cells were incubated with pEtx. (B-D) ATP release from hMAL-GFP or 916 
GFP expressing cells: tsA201 cells (B), RT4-D6P2T cells (C) and HeLa cells 917 
(D). Etx (100 nM) was added (arrow) to transfected cell lines expressing hMAL-918 
GFP or GFP alone and ATP release was monitored as in (A). ATP was 919 
released only from cells expressing hMAL-GFP protein (black line) but not from 920 
cells expressing GFP alone (grey line). Triton X-100 (0.2 % final concentration) 921 
was added at the end of the experiment to estimate the total content of ATP in 922 
cells (not shown). (E) Bar chart shows the percentage of the Etx-induced 923 
release of ATP with respect to the total ATP content in each condition (B-D). 924 
Each condition was run in triplicates and in three independent experiments 925 
(****p<0.0001). 926 
 927 
Figure 3. Cytotoxic effect of Etx on hMAL expressing cells (tsA201, RT4-928 
D6P2T and HeLa).  929 
MTS assay was performed to determine cell viability after incubating the cells 930 
with increasing concentrations of Etx for 1 hour. Results from three 931 
independent experiments were represented as percentage of cell survival 932 
along different Etx concentration. The cytotoxicity of Etx on hMAL-GFP 933 
expressing cells was dose dependent as on MDCK cells, while no effect was 934 
observed on control cells expressing GFP alone. Each condition was run in 935 
triplicates and in three independent experiments (****p<0.0001, for clarity, only 936 
hMAL-GFP expressing cells were labeled with asterisk).  937 
 938 

































Figure 4. Immunoprecipitation assays reveal a direct interaction between 939 
hMAL and Etx. 940 
Coimmunoprecipitation of Etx by anti-GFP antibody in hMAL-GFP HeLa stable 941 
cell line. Cells were treated or not with 100 nM of pEtx or Etx, for 30 minutes. 942 
Immunoprecipitation of hMAL-GFP was performed with anti-GFP antibody (α-943 
GFP); anti-αTubulin antibody (α-Tub) was used as a negative control. Upper 944 
pannel: western blotting revealed with anti-pEtx antibody. On the left, inputs 945 
from cell lysates revealed pEtx and Etx monomers (33 kDa black arrow, and 29 946 
kDa black arrowhead, respectively) and Etx protein complexes (>250 kDa, grey 947 
arrowhead). On the centre, immunoprecipitated samples (IP) with α-GFP or α-948 
Tub, as a negative control. Results showed the coimmunoprecipitation of Etx 949 
complexes (>250 kDa grey arrowhead) from α-GFP IP, but no signal was 950 
detected from α-Tub IP. On the right: pEtx and Etx recombinant proteins. 951 
Asterisk indicates a non-specific band present in all lanes. Lower pannel: 952 
western blot analysis from the same membrane analyzed with α-GFP. hMAL-953 
GFP was detected as a band of 44 kDa. Notice that α-Tub IP do not 954 
immunoprecipitate hMAL-GFP. This is a representative example from a 955 
threefold repeated experiment. 956 
 957 
Figure 5. Lymphocytic cell lines expressing MAL are sensitive to Etx. 958 
(A) RT-PCR detection of endogenous hMAL mRNA on MOLT-4 and Jurkat, 959 
lymphocytic T cell lines, but not on TK6 and JeKo-1 cell lines. The18S rRNA 960 
was used as control. (B) MTS assay was performed, as in figure 3, to determine 961 
cell viability after treatment of cells (JeKo-1, TK6, MOLT-4 and Jurkat) with 962 
increasing concentrations of Etx for 1 hour. The cytotoxicity of Etx on MOLT-4 963 

































and Jurkat cells was dose dependent, while no effect was observed on TK6 and 964 
JeKo-1 lymphocytic B cell lines. Triplicates of three independent experiments 965 
were represented as percentage of cell survival along different Etx 966 
concentrations. (****p<0.0001). (C) Percentage of ATP released from JeKo-1, 967 
TK6, MOLT-4 and Jurkat cells after the treatment with 100nM of pEtx or Etx. 968 
MOLT-4 cells and Jurkat cells were sensitive to Etx, being the ATP release 969 
highest in MOLT-4 cells, whereas no ATP release was observed in JeKo-1 and 970 
TK6 lymphocitic B cell lines. Notice that no ATP release was detected when 971 
cells were incubated with pEtx at the maximum concentration used with Etx 972 
(100 nM). The histograms were obtained from triplicates of three independent 973 
experiments (****p<0.0001). 974 
 975 
Figure 6. Etx cytotoxicity on MOLT-4 and Jurkat Lymphocytic T cell lines 976 
is the result of oligomerization. 977 
(A) Flow cytometry and cell viability of JeKo-1, MOLT-4 and Jurkat cell lines 978 
after Etx incubation. Cells were incubated with 0, 10 and 100 nM of pEtx or Etx 979 
for 20 minutes and analyzed after 7AAD staining. Histogram analysis of 7AAD 980 
signal revealed that MOLT-4 and Jurkat cells were sensitive to Etx while Jeko-1 981 
cells were not sensitive at all (bar indicates death cells stained with 7AAD). 982 
Note that as in the case of Jeko-1, no cells were dying after pEtx incubation. 983 
(Represented results from one of three independent experiments). (B) Bar chart 984 
of cell death percentage from flow cytometry assays explained above. Results 985 
were obtained from three independent experiments (** p=0.0058, ****p=0.0001). 986 
(C) JeKo-1 and MOLT-4 cell lines were treated with 100 nM of pEtx or Etx for 987 
30 min. Western blot analysis of cell lysates using anti-pEtx revealed high 988 

































molecular weight complexes (>250 kDa, black arrowhead) and monomeric 989 
forms of pEtx (33 kDa, black arrow) in MOLT-4 cells, but very low levels or no 990 
detection of pEtx or Etx was observed in JeKo-1 cell line. .  Recombinant pEtx 991 
and Etx were used as controls in the gels to define the correct size bands and 992 
membrane was developed with anti-αTubulin to obtain a loading control signal. 993 
The experiment was repeated three times. 994 
Figure 7. Etx binding depends on MAL expression. 995 
(A) Western blot analysis of MOLT-4 CTL and MOLT4-∆MAL with anti-MAL 996 
(E1) antibody and anti-Flotillin-1 antibody, as a loading control. After applying 997 
Crisp-Cas9 technology, MAL protein was absent on MOLT4-∆MAL cells (upper 998 
panel). . The experiment was repeated tree times. (B) Confocal microscopy 999 
images from MOLT-4 CTL and MOLT4-∆MAL pelleted cells incubated 1000 
previously with 100 nM pEtx-GFP for 45 min. Nuclei were stained with DRAQ5 1001 
(blue). The high density of cells is the result to observe pelleted cells 1002 
resuspended in 20 µl and placed as a drop on a coverslip. Intense fluorescent 1003 
signal due to the pEtx binding was observed on the plasma membrane of 1004 
MOLT-4 CTL cells (green) but not on MOLT4-∆MAL cells. Scale bar 1005 
corresponds to 5 µm. (C) Flow cytometry analyses revealed the absence of Etx 1006 
binding on MOLT-4 ∆MAL cells compared to MOLT-4 CTL after incubation of 1007 
cells with Etx-633 100 nM for 20 min. (D) Flow cytometry analyses after 1008 
incubation with anti-MAL 6D9 followed by Alexa 488 secondary antibody 1009 
showed no anti-MAL 6D9 binding on MOLT-4 ∆MAL cells.  Notice that MOLT-4 1010 
∆MAL revealed no Etx binding nor anti-MAL 6D9 binding due to the absence of 1011 
MAL protein, as happens in JeKo-1 control cells.  1012 
 1013 

































Figure 8. Neither the cytotoxicity nor the Etx binding and their oligomeric 1014 
complexes are detected on MOLT-4 ∆MAL cells. 1015 
(A) MTS assay performed to determine cell viability after incubation of cells with 1016 
increasing concentrations of Etx for 1 h. The cytotoxicity of Etx on MOLT-4 and 1017 
MOLT-4 CTL cells was dose dependent, while no effect was observed on 1018 
MOLT-4 ∆MAL cells. Results represented the percentage of cell survival from 1019 
three independent experiments. (****p<0.0001). (B) MOLT-4 CTL and MOLT-4 1020 
∆MAL cells were treated with 100 nM of pEtx or Etx for 30 min. Western blot 1021 
analysis of cell lysates using anti-pEtx revealed oligomeric complexes (> 250 1022 
kDa, black arrowhead) and also monomeric forms of pEtx (33 kDa, black arrow) 1023 
and Etx (29 kDa, grey arrow) in MOLT-4 CTL. No pEtx or Etx nor oligomeric 1024 
complexes were oberved in MOLT-4 ∆MAL cells. Recombinant pEtx and Etx 1025 
were used as controls in the gels to define the correct size bands and 1026 
membrane was developed with anti-αTubulin to obtain a loading control signal. 1027 
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